Orexo AB (SE:ORX)
:ORX
Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr13.56 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr660.72M
Enterprise Valuekr244.39M
Total Cash (Recent Filing)kr912.40M
Total Debt (Recent Filing)kr492.20M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Jul 22, 2026EPS Estimate
-1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.26
Revenue Forecast (FY)kr21.60M
Bulls Say, Bears Say
Bulls Say
Strengthened Cash PositionThe ZUBSOLV U.S. sale transformed the balance sheet into net cash, creating multi-quarter runway and materially improving liquidity. This durable boost reduces immediate refinancing pressure, permits funding of near‑term clinical milestones, and gives management flexibility to pursue partnering or de‑risk programs without urgent dilutive financing.
Clear R&D Milestones & Pipeline FocusA defined timetable for OX390, OX640 and IZIPRY makes the development path more predictable and allows focused resource allocation. This structural clarity helps prioritize spending, facilitates milestone‑based partnering, and enables investors and partners to assess progress against concrete regulatory and clinical inflection points over the next 12–18 months.
External Non‑Dilutive Funding EmergingBARDA engagement and initial partner funding begin to offset internal cash burn, providing non‑dilutive support for critical OX390 work. Durable third‑party funding reduces reliance on equity or debt, validates program importance to public health partners, and improves the likelihood management can advance trials without accelerating cash depletion.
Bears Say
Minimal Continued‑Operations RevenuePost‑divestment commercial revenue is negligible, leaving Orexo reliant on pipeline milestones and external funding to sustain operations. A structurally thin revenue base limits internal cash generation, heightens dependence on partners/BARDA, and prolongs recovery until new products reach market or licensing deals materialize.
Bond Covenant & Redemption RiskExpected covenant breaches create a material refinancing and liquidity overhang: forced redemption would consume cash or force adverse refinancing, shortening runway and possibly prompting asset sales or dilutive funding. This structural financing uncertainty complicates multi‑quarter planning and raises execution risk for trials.
Ongoing DOJ InvestigationA persistent DOJ probe is a long‑lived legal and reputational risk that can lead to fines, compliance costs, or restrictions on U.S. operations. This uncertainty can deter potential partners, slow commercial discussions, and impose contingent liabilities that affect capital allocation and strategic transactions over multiple quarters.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr13.56 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr660.72M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 22, 2026 which is in 83 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -1.6.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all SE:ORX earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---